- Today's Hot Chat Topics
- Member Benefits
- Manage your personalised Watchlist.
- Set up an online Virtual Portfolio.
- Participate in Share Chat.
- See more trades and director dealings.
- Play the Fantasy Share Trading Game.
Share:
HomeShare PricesStock PickerFinancial DiaryUK IndicesUK Industry SectorsCompany LookupShare RisersShare FallersBroker RatingsFinance GlossarySMS ServicesShare ChatFinance NewsBlogsLive PricesShares BookshopFinance ToolsMembers
Latest Share Chat
Oxford Biomedica Share News (OXB)
Share News for Oxford Biomedica (OXB)
| Share Price: 2.375 | Bid: 2.25 | Ask: 2.50 | Change: 0.00 (0.00%) |  | ||||||
| ||||||||||
BRIEF-Oxford Biomedica reports success in Parkinson's study
Mon, 16th Apr 2012 07:26
LONDON, April 16 (Reuters) - Oxford BioMedica PLC:
* Successful completion of prosavin p
* Meets endpoint prosavin is safe, well-tolerated and mediates long-term
improvement of motor function
((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here)
COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
LONDON, April 16 (Reuters) - Oxford BioMedica PLC:
* Successful completion of prosavin p
hase i/ii study in parkinson's disease
* Meets endpoint prosavin is safe, well-tolerated and mediates long-term
improvement of motor function
((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here)
COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
STOCKS NEWS EUROPE-Oxford BioMedica up on Novartis deal
Shares in Oxford BioMedica rise 15 percent after the gene-based biopharmaceutical specialist signs a deal to make clinical grade material for Novartis[1 May '13]
STOCKS NEWS EUROPE-UK small caps edge down 0.1 pct early on
The FTSE Small Cap index sheds 0.1 percent in early deals, underperforming its larger peers with the FTSE 100 up 0.4 percent and the FTSE 250 rising 0[1 May '13]
BRIEF-Oxford Biomedica says ImaginAb exercises option for licence
LONDON, Nov 29 (Reuters) - Oxford BioMedica PLC: * Imaginab acquires exclusive worldwide licence for 5t4-based imaging diagnostic[29 Nov '12]
UPDATE 1-Oxford Bio abandons prostate cancer vaccine study
LONDON, Oct 10 (Reuters) - Britain's Oxford BioMedica said on Wednesday it was closing a mid-stage clinical trial of its cancer vaccine TroVax[10 Oct '12]
BRIEF-Oxford Bio to close prostate cancer study in U.S.
LONDON, Oct 10 (Reuters) - Oxford BioMedica PLC: * To close phase II study in US to assess Trovax in patients with prostate cancer[10 Oct '12]
BRIEF-Oxford Biomedica to place 11 mln stg
LONDON, June 29 (Reuters) - Oxford BioMedica PLC: * Proposed firm placing of £11 million and open offer of up to £5 million ((London[29 Jun '12]
BRIEF-Oxford Biomedica's manufacturing facility approved
LONDON, June 8 (Reuters) - Oxford BioMedica PLC: * Approval from the UK mhra for manufacturing facility in cowley, Oxford ((London Eq[8 Jun '12]
BRIEF-Oxford Biomedica presents ocular clinical data
LONDON, May 8 (Reuters) - Oxford BioMedica PLC: * Presentation of ocular clinical data at arvo * Early retinostat data indicate susta[8 May '12]
